BR112012001171B1 - Método de evolução e expressão aumentada de um anticorpo ou fragmento de anticorpo que se liga a um antígeno em um hospedeiro de produção de célula de mamífero - Google Patents

Método de evolução e expressão aumentada de um anticorpo ou fragmento de anticorpo que se liga a um antígeno em um hospedeiro de produção de célula de mamífero Download PDF

Info

Publication number
BR112012001171B1
BR112012001171B1 BR112012001171-5A BR112012001171A BR112012001171B1 BR 112012001171 B1 BR112012001171 B1 BR 112012001171B1 BR 112012001171 A BR112012001171 A BR 112012001171A BR 112012001171 B1 BR112012001171 B1 BR 112012001171B1
Authority
BR
Brazil
Prior art keywords
antibody
cells
protein
polypeptide
evolution
Prior art date
Application number
BR112012001171-5A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112012001171A2 (pt
Inventor
Jay Milton Short
Original Assignee
Bioatla, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioatla, Llc filed Critical Bioatla, Llc
Priority to BR122015012748-3A priority Critical patent/BR122015012748B1/pt
Publication of BR112012001171A2 publication Critical patent/BR112012001171A2/pt
Publication of BR112012001171B1 publication Critical patent/BR112012001171B1/pt

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Ecology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112012001171-5A 2009-07-17 2010-07-16 Método de evolução e expressão aumentada de um anticorpo ou fragmento de anticorpo que se liga a um antígeno em um hospedeiro de produção de célula de mamífero BR112012001171B1 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122015012748-3A BR122015012748B1 (pt) 2009-07-17 2010-07-16 Métodos de evolução de um anticorpo ou fragmento de anticorpo

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27116809P 2009-07-17 2009-07-17
US61/271,168 2009-07-17
PCT/US2010/042302 WO2011009058A2 (en) 2009-07-17 2010-07-16 Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts

Publications (2)

Publication Number Publication Date
BR112012001171A2 BR112012001171A2 (pt) 2017-06-13
BR112012001171B1 true BR112012001171B1 (pt) 2021-09-21

Family

ID=43450243

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012001171-5A BR112012001171B1 (pt) 2009-07-17 2010-07-16 Método de evolução e expressão aumentada de um anticorpo ou fragmento de anticorpo que se liga a um antígeno em um hospedeiro de produção de célula de mamífero

Country Status (18)

Country Link
US (6) US8859467B2 (https=)
EP (6) EP3156485B1 (https=)
JP (3) JP6193570B2 (https=)
KR (5) KR20190017070A (https=)
CN (2) CN107090031A (https=)
AU (5) AU2010273974B2 (https=)
BR (1) BR112012001171B1 (https=)
CA (2) CA3034484A1 (https=)
DK (5) DK3156485T3 (https=)
ES (3) ES2701931T3 (https=)
HU (1) HUE029328T2 (https=)
IN (1) IN2012DN00737A (https=)
MX (3) MX392642B (https=)
MY (2) MY160472A (https=)
PL (2) PL2907873T3 (https=)
PT (1) PT3042957T (https=)
SG (3) SG10201700096VA (https=)
WO (1) WO2011009058A2 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201700096VA (en) * 2009-07-17 2017-02-27 Bioatla Llc Simultaneous, Integrated Selection And Evolution Of Antibody/Protein Performance And Expression In Production Hosts
WO2011109726A2 (en) * 2010-03-05 2011-09-09 Bioatla Llc Homologous multi-specific antibodies
ES2741175T3 (es) 2010-07-16 2020-02-10 Bioatla Llc Nuevos métodos de evolución de proteínas
AU2015242961B2 (en) * 2010-07-16 2017-03-02 Bioatla, Llc Novel methods of protein evolution
MX349622B (es) 2010-09-08 2017-08-07 Halozyme Inc Metodos para evaluar e identificar o evolucionar proteinas terapeuticas condicionalmente activas.
EP2773964A4 (en) * 2011-11-03 2015-06-24 Stc Biolog Inc METHOD FOR DETERMINING THE PHARMACOLOGICAL PROPERTIES OF RECOMBINANT PROTEINS
HK1221908A1 (zh) 2013-04-29 2017-06-16 Adimab, Llc 多特异(polyspecificity)试剂，其制备方法和用途
EP3447493B1 (en) * 2014-01-07 2020-05-13 Bioatla, LLC Proteins targeting orthologs
GB201407852D0 (en) 2014-05-02 2014-06-18 Iontas Ltd Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
ES2913205T3 (es) * 2014-05-13 2022-06-01 Bioatla Inc Proteínas biológicas activas condicionalmente
WO2016004242A1 (en) * 2014-07-01 2016-01-07 Stc Biologics, Inc. A method for development of recombinant proteins with fingerprint like similarity to the reference product
DK4074735T3 (da) 2014-08-28 2025-07-14 Bioatla Inc Betinget aktive kimæriske antigenreceptorer til modificerede t-celler
WO2016036916A1 (en) 2014-09-03 2016-03-10 Bioatla, Llc Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts
EP3262217A4 (en) 2015-02-24 2018-07-18 BioAtla LLC Conditionally active biological proteins
PE20181363A1 (es) * 2015-09-23 2018-08-27 Genentech Inc Variantes optimizadas de anticuerpos anti-vegf
WO2017078839A1 (en) 2015-11-02 2017-05-11 Bioatla, Llc Conditionally active polypeptides
PL3455261T3 (pl) 2016-05-13 2022-12-12 Bioatla, Inc. Przeciwciała anty-ror2, fragmenty przeciwciał, ich immunokoniugaty oraz ich zastosowania
AU2018301393B2 (en) 2017-07-11 2025-02-27 Compass Therapeutics Llc Agonist antibodies that bind human CD137 and uses thereof
WO2019089753A2 (en) 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
EP3713961A2 (en) 2017-11-20 2020-09-30 Compass Therapeutics LLC Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
US11046769B2 (en) 2018-11-13 2021-06-29 Compass Therapeutics Llc Multispecific binding constructs against checkpoint molecules and uses thereof
CN113924118A (zh) 2019-04-18 2022-01-11 百时美施贵宝公司 在低ph下具有增强的结合特异性的伊匹单抗变体
US20240124889A1 (en) 2019-05-07 2024-04-18 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
CN111048154B (zh) * 2019-12-10 2023-06-06 上海药明生物技术有限公司 一种抗体表位作图的方法
CN111462815B (zh) * 2020-03-27 2023-05-02 上海祥耀生物科技有限责任公司 一种抗体库的构建方法及装置
US11506060B1 (en) * 2021-07-15 2022-11-22 Honeywell International Inc. Radial turbine rotor for gas turbine engine
WO2023044483A2 (en) 2021-09-20 2023-03-23 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2023220695A2 (en) 2022-05-13 2023-11-16 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
JP2025528068A (ja) 2022-08-03 2025-08-26 ボイジャー セラピューティクス インコーポレイテッド 血液脳関門を通過させるための組成物及び方法
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4361549A (en) 1979-04-26 1982-11-30 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4957858A (en) 1986-04-16 1990-09-18 The Salk Instute For Biological Studies Replicative RNA reporter systems
US4883750A (en) 1984-12-13 1989-11-28 Applied Biosystems, Inc. Detection of specific sequences in nucleic acids
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
AU622104B2 (en) 1987-03-11 1992-04-02 Sangtec Molecular Diagnostics Ab Method of assaying of nucleic acids, a reagent combination and kit therefore
CA1323293C (en) 1987-12-11 1993-10-19 Keith C. Backman Assay using template-dependent nucleic acid probe reorganization
ATE92538T1 (de) 1988-01-21 1993-08-15 Genentech Inc Verstaerkung und nachweis von nukleinsaeuresequenzen.
CA1340807C (en) 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
JP2856804B2 (ja) 1988-03-24 1999-02-10 ユニバーシティ オブ アイオワ リサーチ ファウンデイション 標識された相補的核酸プローブを開裂する触媒反応の補因子としての活性に基づく核酸配列検出のための触媒ハイブリッド形成系
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP1361273A3 (en) 1992-11-24 2004-02-11 G.D. Searle & Co. Interleukin-3 (IL-3) multiple mutation polypeptides
US6171820B1 (en) 1995-12-07 2001-01-09 Diversa Corporation Saturation mutagenesis in directed evolution
US6562594B1 (en) 1999-09-29 2003-05-13 Diversa Corporation Saturation mutagenesis in directed evolution
US6764835B2 (en) 1995-12-07 2004-07-20 Diversa Corporation Saturation mutageneis in directed evolution
US20030219752A1 (en) * 1995-12-07 2003-11-27 Diversa Corporation Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof
US6238884B1 (en) 1995-12-07 2001-05-29 Diversa Corporation End selection in directed evolution
US8137906B2 (en) 1999-06-07 2012-03-20 Sloning Biotechnology Gmbh Method for the synthesis of DNA fragments
US7033781B1 (en) 1999-09-29 2006-04-25 Diversa Corporation Whole cell engineering by mutagenizing a substantial portion of a starting genome, combining mutations, and optionally repeating
US7163681B2 (en) * 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
CN100522242C (zh) 2001-02-19 2009-08-05 默克专利有限公司 具有降低的免疫原性的人工蛋白质
US7117096B2 (en) 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
WO2002092780A2 (en) * 2001-05-17 2002-11-21 Diversa Corporation Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof
US7647184B2 (en) * 2001-08-27 2010-01-12 Hanall Pharmaceuticals, Co. Ltd High throughput directed evolution by rational mutagenesis
BRPI0412007A (pt) * 2003-06-27 2006-08-15 Bioren Inc mutagênese look-through
GB0520169D0 (en) * 2005-10-04 2005-11-09 Celltech R&D Ltd Biological products
KR20080073293A (ko) 2005-10-14 2008-08-08 메디뮨 엘엘씨 항체 라이브러리의 세포 디스플레이
EP2617827A1 (en) * 2007-03-26 2013-07-24 Celexion, LLC Method for displaying engineered proteins on a cell surface
US7947495B2 (en) 2007-11-01 2011-05-24 Abbott Biotherapeutics Corp. Immunoglobulin display vectors
JP5513398B2 (ja) 2007-11-02 2014-06-04 ザ スクリプス リサーチ インスティチュート 非天然アミノ酸を含有する蛋白質を使用する指向的進化
US8312249B1 (en) 2008-10-10 2012-11-13 Apple Inc. Dynamic trampoline and structured code generation in a signed code environment
SG10201700096VA (en) 2009-07-17 2017-02-27 Bioatla Llc Simultaneous, Integrated Selection And Evolution Of Antibody/Protein Performance And Expression In Production Hosts
FR2957821B1 (fr) 2010-03-24 2014-08-29 Inst Francais Du Petrole Nouvelle zone de regeneration du catalyseur divisee en secteurs pour unites catalytiques regeneratives

Also Published As

Publication number Publication date
AU2019203813B2 (en) 2021-03-11
US20210207129A1 (en) 2021-07-08
US20120245036A1 (en) 2012-09-27
WO2011009058A2 (en) 2011-01-20
HK1210623A1 (en) 2016-04-29
BR112012001171A2 (pt) 2017-06-13
DK3406717T3 (da) 2020-03-16
JP2012533307A (ja) 2012-12-27
AU2015243076B2 (en) 2017-02-23
EP3156485A1 (en) 2017-04-19
HUE029328T2 (en) 2017-02-28
EP3042957A1 (en) 2016-07-13
MX392642B (es) 2025-03-19
AU2021203220A1 (en) 2021-06-10
EP2454376A2 (en) 2012-05-23
KR20120069664A (ko) 2012-06-28
MY173037A (en) 2019-12-20
SG10201505075TA (en) 2015-07-30
AU2010273974B2 (en) 2016-01-14
US10106788B2 (en) 2018-10-23
EP3042957B1 (en) 2017-09-13
EP3406717B1 (en) 2019-12-11
AU2015243076A1 (en) 2015-11-05
JP6193913B2 (ja) 2017-09-06
AU2017203243B2 (en) 2019-07-11
PT3042957T (pt) 2017-12-21
CN107090031A (zh) 2017-08-25
EP3156485B1 (en) 2018-09-12
JP2017205110A (ja) 2017-11-24
KR20210013294A (ko) 2021-02-03
DK3156485T3 (en) 2019-01-07
CN102625848A (zh) 2012-08-01
KR20220002712A (ko) 2022-01-06
MX347654B (es) 2017-05-05
AU2010273974A1 (en) 2012-02-09
AU2010273974A8 (en) 2012-02-23
SG177687A1 (en) 2012-02-28
AU2019203813A1 (en) 2019-06-20
ES2701931T3 (es) 2019-02-26
DK3636759T3 (da) 2023-10-23
CA2768247C (en) 2019-04-09
WO2011009058A3 (en) 2011-04-14
EP2454376B1 (en) 2015-12-02
CA2768247A1 (en) 2011-01-20
US20240263354A1 (en) 2024-08-08
EP3636759B1 (en) 2023-10-11
IN2012DN00737A (https=) 2015-06-19
EP3636759A1 (en) 2020-04-15
ES2652340T3 (es) 2018-02-01
EP2907873B1 (en) 2016-04-06
US10047357B2 (en) 2018-08-14
EP2907873A1 (en) 2015-08-19
US10920216B2 (en) 2021-02-16
JP2015211672A (ja) 2015-11-26
JP6193570B2 (ja) 2017-09-13
CA3034484A1 (en) 2011-01-20
KR101823872B1 (ko) 2018-01-31
BR122015012748A2 (pt) 2020-01-07
MY160472A (en) 2017-03-15
ES2581318T3 (es) 2016-09-05
SG10201700096VA (en) 2017-02-27
DK3042957T3 (en) 2018-01-02
US20180371452A1 (en) 2018-12-27
KR20180010347A (ko) 2018-01-30
PL3042957T3 (pl) 2018-03-30
US20150024944A1 (en) 2015-01-22
US20120165201A1 (en) 2012-06-28
EP2454376A4 (en) 2013-07-10
AU2017203243A1 (en) 2017-06-08
KR20190017070A (ko) 2019-02-19
PL2907873T3 (pl) 2016-10-31
AU2021203220B2 (en) 2023-05-04
EP3406717A1 (en) 2018-11-28
DK2907873T3 (en) 2016-06-13
US8859467B2 (en) 2014-10-14
US11976381B2 (en) 2024-05-07
MX2012000803A (es) 2012-06-01
JP6681131B2 (ja) 2020-04-15

Similar Documents

Publication Publication Date Title
AU2021203220B2 (en) Simultaneous, Integrated Selection and Evolution of Antibody/Protein Performance and Expression in Production Hosts
US10829513B2 (en) Methods of protein evolution
HK40026409A (en) Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
BR122015012748B1 (pt) Métodos de evolução de um anticorpo ou fragmento de anticorpo
HK1236221A1 (en) Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
HK1236221B (en) Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
HK1230231B (en) Simultaneous, integrated selection and evolution of human protein performance and expression in production hosts
HK1230231A1 (en) Simultaneous, integrated selection and evolution of human protein performance and expression in production hosts
HK1210623B (en) Simulataneous, integrated selection and evolution of antibody/protein performance and expression in production hosts

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: BIOATLA, LLC (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/07/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.